CBD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 07, 2022. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 40 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 80%.
The Momentum Indicator moved below the 0 level on June 03, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on CBD as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for CBD moved below the 200-day moving average on June 16, 2022. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CBD entered a downward trend on July 01, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CBD advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .
CBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.304) is normal, around the industry mean (2.218). P/E Ratio (7.342) is within average values for comparable stocks, (122.842). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.492). Dividend Yield (0.023) settles around the average of (0.033) among similar stocks. CBD's P/S Ratio (0.084) is slightly lower than the industry average of (0.690).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of supermarkets
|MFs / NAME||Price $||Chg $||Chg %|
|Allspring Special Mid Cap Value R6|
|Nationwide Mid Cap Market Idx A|
|Ecofin Global Energy Transition A|
|Putnam International Value R|
|JHancock Disciplined Value Intl C|
A.I.dvisor tells us that CBD and JWN have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CBD and JWN's prices will move in lockstep.
|JWN - CBD|
|M - CBD|
|KSS - CBD|
|DDS - CBD|
|DDT - CBD|